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The isolation of the coronavirus (CoV) identiﬁ  ed as the 
cause of severe acute respiratory syndrome and the detec-
tion of 2 new human CoVs (HCoV-NL63 and HCoV-HKU1) 
have led to studies of the epidemiology and clinical and 
socioeconomic effects of infections caused by all HCoVs, 
including those known since the late 1960s (HCoV-229E 
and HCoV-OC43). HCoV infections can be associated with 
respiratory and extrarespiratory manifestations, including 
central nervous system involvement. Furthermore, unlike 
other RNA viruses, HCoVs can easily mutate and recombine 
when different strains infect the same cells and give rise to a 
novel virus with unpredictable host ranges and pathogenic-
ity. Thus, circulating HCoVs should be closely monitored to 
detect the spread of particularly virulent strains in the com-
munity at an early stage and to facilitate the development of 
adequate preventive and therapeutic measures.
H
uman coronaviruses (HCoVs) have been known since 
the late 1960s as a group of viruses capable of infecting 
humans and animals (1). In a wide variety of animals, they 
cause respiratory, enteric, hepatic, and neurologic diseases 
that, in some cases (especially when they infect the young), 
can be severe (1). However, until the pathogen identiﬁ  ed 
as the cause of severe acute respiratory syndrome (SARS) 
was isolated (2), the previously known HCoVs (HCoV-
229E and HCoV-OC43) were considered to play a marginal 
clinical role in pediatrics. This conclusion was made main-
ly because, on the basis of the data available at the time, 
HCoVs were believed to cause only mild upper respiratory 
tract infections (URTIs) in children and that only in pre-
mature infants and children with a chronic underlying dis-
ease could severe lower respiratory tract infections (LRTIs) 
develop (3). Moreover, no importance was placed on re-
ports that suggested a possible relationship with the de-
velopment of extrarespiratory problems, including central 
nervous system (CNS) involvement, in which HCoVs can 
persist and play a role in causing chronic neurologic disor-
ders (4). Consequently, the circulation of HCoVs was not 
monitored, and no attempt was made to develop vaccines 
or drugs that were active against the viruses.
The identiﬁ   cation of SARS-CoV and the isolation 
of 2 novel HCoVs in humans (HCoV-NL63 and HCoV-
HKU1) (5,6) have led to several studies of the epidemiol-
ogy and clinical and socioeconomic effects of HCoV in-
fections, which were greatly facilitated by the availability 
of modern molecular biology methods that enable direct 
viral identiﬁ  cation in respiratory secretions (7–26). Interest 
was strengthened by the demonstration that SARS could 
be considered a zoonotic infection because, after it was 
described and the causative agent identiﬁ  ed from patients 
in the People’s Republic of China, SARS-CoV–like viruses 
were isolated from caged animals, including palm civets 
and raccoon dogs in wildlife markets of the same Chinese 
province (27). This ﬁ  nding and the subsequent independent 
discovery of SARS-CoV–like viruses in horseshoe bats in-
dicated that wild animals could be the reservoir of these vi-
ruses and that, in a suitable environment, they could infect 
humans and cause epidemics. New data concerning old and 
the new HCoVs raise the question of whether HCoVs may 
be more clinically important in children than was previous-
ly thought, thus indicating the need for a systematic evalu-
ation of their circulation and the availability of preventive 
and therapeutic measures.
Epidemiology of HCoV Infections in Children
A profound difference exists between the epidemiol-
ogy of the infections caused by SARS-CoV and that of all 
other HCoV infections. SARS-CoV emerged in November 
2002 and disappeared in April 2004 (28). During these 18 
months, it was isolated in many countries, some of which 
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were very distant from each other. However, the total of 
8,098 cases of SARS diagnosed worldwide (28) is substan-
tially fewer than the number usually found during epidem-
ics of the most common respiratory viruses, such as respi-
ratory syncytial virus (RSV) and inﬂ  uenza viruses (18).
Furthermore, seroepidemiologic studies of high-risk 
and low-risk residential areas have clearly shown that the 
prevalence of immunoglobulin G against SARS-CoV was 
low in children and adults (29); this result indicates that 
SARS-CoV not only had a restricted period of circulation 
but also that it had limited spread. Proportionally fewer 
children were involved: <5% of all cases were diagnosed 
in patients <18 years of age (28). The biology of SARS and 
its low level of transmissibility seem to be the main rea-
sons for the low risk for contagion in children. In most of 
the areas in which outbreaks occurred, healthcare workers 
and adult patients were mainly involved and, because they 
were immediately hospitalized, the risk for the infection 
spreading to children was greatly reduced because they are 
not usually allowed to visit hospitals (28). This hypothesis 
seems to be further supported by the fact that the early de-
tection and isolation of symptomatic patients were the most 
important measures in controlling the SARS epidemic.
Unlike SARS-CoV, HCoV-229E, HCoV-OC43, 
HCoV-NL63, and HCoV-HKU1 have been in continuous 
circulation since their ﬁ  rst isolation and every year cause 
a large number of infections that more frequently involve 
children than adults (3,5–26). In particular, the data re-
garding the earlier-appearing HCoVs indicate that they are 
distributed throughout the world and mainly circulate dur-
ing the winter and early spring, with outbreaks occurring 
every 2–4 years (3). Whenever HCoVs have been sought 
in studies of respiratory infections in infants and children, 
they have been found, although generally less frequently 
than other respiratory viruses such as RSV and inﬂ  uenza 
(18,30). However, the real importance of HCoV-229E and 
HCoV-OC43 in clinical practice has not been fully deﬁ  ned 
because the collected data are often discordant. In 1974, 
McIntosh et al. found that the global incidence of LRTIs 
due to HCoV-229 and HCoV-OC43 in hospitalized children 
was no higher than 3.8% (31). Later studies have shown that 
when all respiratory infections are considered, the etiologic 
prevalence of these pathogens in pediatric patients can be 
signiﬁ  cantly higher, varying from ≈5% to >30% (7,15).
An overall evaluation of the available data suggests 
that these differences can be attributed to differences in 
research methods. The infections caused by these viruses 
are more common from November through March; more 
frequently affect children <5 years of age, those examined 
in the community, and those without underlying risk fac-
tors; and are more often identiﬁ  ed with serologic methods 
(32,33). In this regard, 2 recent surveys that used serologic 
methods alone found previous HCoV-229E infection in 
42.9%–50.0% of children 6–12 months of age (32) and in 
65% of those 2.5–3.5 years of age (33). Similarly, in 75% 
of the cases, children 2.5–3.5 years of age had antibodies 
against HCoV-NL63 (33). All these factors can explain 
why the lowest incidences of HCoV-229E and HCoV-
OC43 infections are usually found when the study popula-
tion includes older children or adolescents, patients with 
underlying severe chronic diseases or hospitalized patients, 
when only highly symptomatic infections are considered, 
and when the study is conducted during the whole year.
Moreover, what has been clearly shown is that the 
original HCoVs are commonly detected in childhood and 
frequently isolated in the nasopharyngeal secretions of 
children with respiratory infection. In some cases, co-in-
fections with other respiratory viruses, mainly RSV, inﬂ  u-
enza viruses, and human metapneumovirus, have also been 
found (4,7–23). However, the real incidence of HCoV-
229E and HCoV-OC43 co-infections with other respiratory 
pathogens has not yet been deﬁ  ned because only a few of 
the published studies were planned to identify all the main 
respiratory viruses.
Similar conclusions can be drawn in relation to the 
more recently identiﬁ  ed HCoVs. HCoV-NL63, which can 
be found in 1.0%–9.3% of nasopharyngeal aspirates from 
patients with RTIs (7–23), circulates throughout the world 
(predominantly during the winter in temperate regions), in-
fects mainly younger children and subjects with underlying 
severe chronic diseases, and is more frequently found in 
nonhospitalized children (online Appendix Table, www.
cdc.gov/EID/content/16/2/183-appT.htm). Although it was 
not isolated until 2000, HCoV-NL63 has probably been 
circulating for some time because one of the ﬁ  rst detec-
tions occurred in a sample of nasopharyngeal secretions 
collected from a child with pneumonia that had been kept 
in a freezer since January 2003 before evaluation (5).
HCoV-HKU1 was identiﬁ  ed in 2005 and has once 
again been found in nasopharyngeal secretions of children 
and adults with respiratory infections in countries that are 
very distant from each other. Its incidence varies from 
<1% to 6% (Table) (6,20,24–26), and seroepidemiologic 
surveys based on antibodies reacting with the recombinant 
HKU1 nucleocapsid protein suggest that infection may be 
relatively common in humans, although generally asymp-
tomatic (32,33). HCoV-NL63 and HCoV-HKU1 are often 
associated with co-infections with other respiratory viruses, 
mainly RSV and inﬂ  uenza viruses (7–26). 
Clinical Manifestations of HCoV 
Infections in Children
Respiratory Problems
It is well known that all HCoVs cause respiratory in-
fections. SARS-CoV is the most aggressive, although the 
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disease seems to be substantially less severe in children 
than in adults. In patients <12 years of age, the clinical 
course of SARS was generally milder and shorter than in 
those >12 years: no death was reported, only 5% of the 
infected children were admitted to an intensive care unit, 
and <1% required mechanical ventilation (28). Leung and 
Chiu found that several children with SARS-CoV infection 
recovered without any sequelae after receiving supportive 
therapy alone (36). The only pediatric patients with severe 
respiratory problems associated with SARS-CoV infection 
were >12 years (36). The clinical picture in persons <12 
years was similar to that caused by other respiratory virus-
es, including inﬂ  uenza viruses. Moreover, the extrarespira-
tory manifestations of SARS-CoV infection described in 
adults (hepatitis and CNS dysfunction) have never been 
reported in children.
The clinical role of all non-SARS CoVs seems to be 
similar: in most healthy children: they cause URTIs that 
spontaneously disappear in a few days. This ﬁ  nding  is 
clearly shown by our data indicating no difference in the 
incidence and clinical severity of the diseases associated 
with HCoV-229E, HCoV-OC43, and HCoV-NL63. Re-
gardless of the HCoV causing the infection, >50% of the 
children had a common cold or pharyngitis, and laboratory 
and radiologic investigations were required in <15% (18). 
Moreover, we also found that the socioeconomic effects of 
these viruses on the families of the infected children was 
marginal: the viruses spread signiﬁ  cantly less than inﬂ  u-
enza viruses among household members, caused only a 
limited number of similar infections in the family, and led 
to fewer lost working or school days (18).
Although possible, the association of non-SARS 
HCoV infection and LRTI is uncommon in healthy chil-
dren. In most published studies, the incidence of pneumo-
nia or bronchiolitis was <5% (7–26,34). Differences in the 
incidence of LRTIs among studies can at least partially 
be attributed to the different prevalence of co-infections. 
Gerna et al. found a high incidence of HCoV-229E, HCoV-
OC43, and HCoV-NL63 infections in infants and children 
with bronchitis, bronchiolitis, or pneumonia, but most of 
the LRTIs were demonstrated in children co-infected with 
HCoVs and other respiratory viruses (37). Furthermore, 
the method used to collect respiratory samples can also 
play a role in explaining the greater incidence of LRTIs 
(11,14,16,22). In this regard, it is important to emphasize 
that when only hospitalized patients (with, consequently, 
only the most severe cases) are enrolled, the incidence of 
LRTIs seems greater (34,37).
Unlike in healthy children, the development of severe 
clinical features after infection with non-SARS HCoV is 
relatively common among newborns, premature and low 
birthweight infants, and children at risk because of under-
lying health problems. Gagneur et al. described 3 HCoV-
229E–related outbreaks in a pediatric and neonatal inten-
sive care unit in France during 1998 (38), and 75% of the 
neonates and 92% of the extremely premature infants were 
symptomatic. Kuypers et al. studied the contribution of 
non-SARS HCoVs to acute RTIs and found that several 
children with isolated HCoV disease had an underlying 
medical condition (21).
Recently collected data concerning the individual vi-
ruses indicate that HCoV-NL63 may be more frequently 
associated with croup than with HCoV-229E or HCoV-
OC43. Van der Hoek et al. found that 9 (45%) of 20 chil-
dren infected by HCoV-NL63 alone, and 12 (25%) of 49 
HCoV-NL63–positive children as a whole, had croup, 
compared with 54 (6%) of 900 HCoV-NL63–negative 
children (p<0.001) (16). Wu et al. (22) and Han et al. (35) 
also reported a high prevalence of croup in children infect-
ed with HCoV-NL63. Furthermore, other reports indicate 
that both HCoV-NL63 (9,12,15,16,21) and HCoV-HKU1 
(20,26) are associated with the development of bronchioli-
tis and wheezing.
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Table. Main studies of the epidemiology and clinical relevance of HCoV-HKU1 in infants and children* 
Study  Location and period  Population
No.
samples
tested
No. (%) patients 
with positive test 
results  Comments
Lau et al. (20) Hong Kong;
2004 Apr–2005 Mar
629 children with RTIs, 6 
mo–5 y; inpatients 
629 10 (1.6) 11 patients with URTIs, 1 
with pneumonia, 1 with 
bronchiolitis, 5 with  febrile 
seizures; 3 with underlying 
disease
Vabret et al. (24) Canada;
2005 Feb–Mar
83 children with RTIs, <5 y; 
negative for RSV, influenza 
A/B, PIV 1–3, adenovirus; 
inpatients
83 5 (6.0) 3 patients with 
gastroenteritis, 1 with febrile 
seizures; mean age 26 mo
Sloots et al. (25) Australia;  
2004 May–Aug 
259 children with RTIs, <5 y; 
inpatients and outpatients
259 10 (3.8) 1 patient with co-infection
Talbot et al. (34) USA;  
2001 Oct–2003 Sep 
1,055 children with RTIs, <5 
y; inpatients 
1,055 4 (0.4)  Mild episodes 
*HCoV, human coronavirus; RTI, respiratory tract infection; URTI, upper respiratory tract infection; RSV, respiratory syncytial virus; PIV, parainfluenza 
virus. PERSPECTIVE
Extrarespiratory Problems
As mentioned above, SARS-CoV does not seem to 
cause extrarespiratory problems in children, but all of the 
other HCoVs can be associated with signs and symptoms 
involving organs and systems other than the respiratory 
tract. Abdominal pain, emesis, and diarrhea can be the ﬁ  rst 
signs and symptoms of an acute infection due to non-SARS 
CoVs. These manifestations have been reported, particu-
larly in the cases of HCoV-OC43 and HCoV-NL63, and 
seem to be the direct consequences of viral invasion of the 
intestinal mucosa, as suggested by the presence of HCoV-
like particles in the stool samples of many patients with 
acute disease (3,7–23).
Non-SARS CoV infections have also been associated 
with acute and chronic CNS diseases (4,20), although no 
clear evidence has shown that the viruses played a direct 
causative role. Nevertheless, some evidence exists of a pos-
sible relationship between HCoV infection and CNS dam-
age. HCoV-229E and HCoV-OC43 infections have been 
associated with the development of various chronic neuro-
logic disorders, including multiple sclerosis, because these 
viruses have been found more frequently in the autopsied 
brain tissue of patients with these diseases more frequently 
than in healthy patients (4). A possibly causative role of 
HCoV-OC43 in determining chronic brain damage is fur-
ther supported by the fact that chronic demyelinisation of 
mouse CNS can be induced by infection with another CoV, 
mouse hepatitis virus (MHV), which belongs to the same 
antigenic group as HCoV-OC43 and has structural similari-
ties with it (39).
Because MHV induces the secretion of pro-inﬂ  am-
matory molecules, such as interleukin-1β (IL-1β), tumor 
necrosis factor, IL-6, and macrophage-inﬂ  ammatory 1β, 
during the infection of neural cells, HCoV-OC43 may act 
similarly in the CNS of infected children and lead to se-
vere brain damage. Furthermore, SARS-CoV (which has 
many genetic similarities to both viruses) seems to cause 
lung damage by activating the same pro-inﬂ  ammatory mol-
ecules, because a particularly high level of circulating IL-
1β has been found in children with SARS (34).
An association of acute neural disease with HCoV in-
fection has been clearly demonstrated by the detection of 
HCoV-OC43 in the cerebrospinal ﬂ  uid of a child presumed 
to have acute disseminated encephalomyelitis, and the fre-
quent association between HCoV-HKU1 infection and the 
development of febrile seizures seems to lead to the same 
conclusion. Lau et al. studied 10 children infected by this 
virus and found that half were affected by febrile seizures, 
the highest prevalence among all the HCoVs (20). Because 
the fever in all of these children was not particularly high 
and lasted for a shorter period than fever associated with 
other viral respiratory infections, it was considered unlike-
ly that all were simple febrile seizures, but possible that 
they may represent speciﬁ  c neurologic damage induced by 
HCoV-HKU1 or that the virus may trigger a negative im-
mune response.
Finally, Esper et al. identiﬁ  ed HCoV-NL63 in respira-
tory specimens from 8 (72.7%) of 11 children with Kawa-
saki disease (KD) and in only 1 (4.5%) of 22 age-matched 
controls, thus suggesting that KD may be triggered by a 
response to HCoV-NL63 infection (40). However, the ﬁ  nd-
ings of other studies do not support this observation, and 
so the question of the causative role of HCoV-NL63 in the 
development of KD remains unanswered.
Assessment of the Importance of 
Known HCoVs in Children
Superﬁ  cial analysis of all of the available data con-
cerning the effects of HCoVs in children suggests that 
the assessment of the importance of HCoVs made before 
SARS-CoV was identiﬁ  ed can still be considered valid. In 
general, all of these viruses (including SARS-CoV) have 
been conﬁ  rmed as mainly respiratory viruses with limited 
clinical relevance in children. They cause mainly URTIs, 
are not frequently isolated in hospitalized children (7–26), 
and, because they are rarely transmitted to other household 
members, have a marginal socioeconomic effects on fami-
lies (18). Even SARS-CoV infection, which had a dramatic 
effect on adults, was mainly associated with relatively mild 
disease in almost all patients <12 years of age (28,34). 
Moreover, most children with a diagnosis of severe respi-
ratory syndrome in whom a HCoV was isolated were co-
infected by other respiratory viruses (7–26). These ﬁ  nding 
suggest that the severity of the respiratory disease at least 
in some of these cases was attributable to the second virus.
Because only premature infants, neonates with a low 
birthweight, and children with an underlying severe chron-
ic disease are at risk of experiencing a severe respiratory 
problem associated with HCoV infection (21,37), we could 
conclude that no further studies of the role of HCoVs in chil-
dren are needed because what is already known is enough 
to make such investigations superﬂ  uous. Furthermore, on 
the basis of the data regarding the natural outcome of re-
spiratory infections, developing vaccines or speciﬁ  c drugs 
appear to be unnecessary.
However, different conclusions can be drawn when the 
global spectrum of the diseases caused by these viruses in 
animals and humans is considered. It is now well known 
that an enormous reservoir of CoVs exists among animals, 
particularly horseshoe bats, and that CoV isolates recovered 
from animals in China have up to 99.8% nucleotide iden-
tity with SARS-CoV (27). Because CoVs can easily mu-
tate, this means that (as in 2003) sustained exposure to the 
infected animals can lead to a SARS-like CoV strain that 
is newly adapted to infect humans and capable of causing 
the reappearance of SARS. Moreover, it has been shown 
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experimentally and in nature that all CoVs undergo a high 
rate of genetic mutations and can recombine when 2 dif-
ferent strains infect the same cells (1). This ﬁ  nding means 
that it is theoretically possible that future situations similar 
to those involving SARS-CoV may involve CoVs that cur-
rently infect only some animals, thus leading to novel vi-
ruses with unpredictable host ranges and pathogenicity.
Phylogenetic analyses of the genes spanning the 
HCoV-HUK1 genome suggest that this virus may be the 
result of a recombination event between related but distinct 
HCoVs (6) and that SARS-CoV may have originated from 
a unique recombination (2). In this regard, the behavior of 
CoVs could be quite similar to that of inﬂ  uenza viruses, 
for which genetic changes and recombinations of avian or 
swine strains are required to allow them to cross the species 
barrier and replicate in humans to cause a pandemic.
Consequently, as is usually the case with inﬂ  uenza, a 
systematic evaluation of the characteristics of CoVs should 
be planned. Patients with severe respiratory syndrome 
seem to be the best target for this kind of evaluation and, in 
this population, studies of children (in whom the incidence 
of infection is higher) may also have application to adults 
because the ﬁ  ndings may lead to a reduction in the risk for 
the spread of particularly virulent HCoV strains.
In addition to the risk for a pandemic related to the re-
appearance of SARS or other new CoVs, the data regarding 
the possible relationship between HCoV infection and CNS 
diseases also suggest the need for a systematic evaluation 
of the circulation of CoVs. If >1 HCoVs are demonstrated 
to play a real role in causing some of the CNS diseases with 
which they have been associated, substantial changes would 
be required in our diagnostic, prophylactic, and therapeutic 
approaches to many neurologic illnesses in children.
Conclusions
HCoV infections can be associated with respiratory 
and extrarespiratory manifestations, including central ner-
vous system involvement. The clinical and genetic charac-
teristics of circulating HCoVs in the pediatric population 
should be monitored to detect the spread of particularly 
virulent HCoV strains in the community at an early stage 
and, if required, to facilitate the development of adequate 
preventive and therapeutic measures.
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